Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Addrenex Pharmaceuticals has reported the filing of a new drug application or NDA for its first drug, CloniBID, to treat hypertension.
Subscribe to our email newsletter
Upon approval from the FDA, Addrenex and its licensing partner Sciele Pharma, will launch the drug in the first half of 2009.
Patrick Fourteau, CEO of Sciele, said: “We congratulate Addrenex on this NDA filing with the FDA. Our partnership with Addrenex provides us with the opportunity to further expand and diversify our product portfolio.”